Overview
To prospectively evaluate the effectiveness and safety of SBRT in the treatment of residual malignant pulmonary nodules after lung cancer, and is committed to providing new treatment options for patients with multiple primary malignant pulmonary nodules who cannot tolerate multiple operations.
Eligibility
Inclusion Criteria:
(1) Age 18-75 years old; (2) ECOG score 0-2 points; (3) Chest CT showed at least two lung
nodules (pure ground glass, partial solid or solid nodules); (4) At least one lesion has
been pathologically diagnosed as lung cancer (T1N0M0-T1N1M0); (5) At least one residual
pulmonary nodule has been diagnosed pathologically or multidisciplinary diagnosis and
treatment (MDT) discussed and considered as a primary malignant pulmonary nodule; (6) The
residual lung nodules are inoperable or operable but the patient refuses to be surgically
removed; (7) Have self-consciousness and can sign informed consent; (8) Must be able to
swallow tablets.
Exclusion Criteria:
(1) There are metastatic pulmonary nodules; (2) Have received chest radiotherapy in the
past; (3) Lymph node metastasis or distant metastasis; (4) The tumor is located in the
proximal bronchial tree area. The proximal bronchial tree is defined as carina, left and
right main bronchus, left and right upper lobe bronchus, middle bronchus, right middle lobe
bronchus, lingual bronchus, left and right lower lobe bronchi; the proximal bronchial tree
area is defined as surrounding the proximal bronchial tree in all directions The area
within 2cm above; (5) Pneumonectomy patients; (6) Severe primary diseases such as heart,
liver, kidney, hematopoietic system, etc.; (7) Women during pregnancy and lactation; (8)
Active period of the human immunodeficiency virus (HIV) infection; (9) Those with active
systemic infection, pneumonia, tuberculosis, and pericarditis; (10) There is a history of
psychotropic drug abuse or drug abuse;(11)Insulin dependent diabetes;(12) Thyroid disease